212 related articles for article (PubMed ID: 28649742)
21. Chromatin remodeling by the CHD7 protein is impaired by mutations that cause human developmental disorders.
Bouazoune K; Kingston RE
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19238-43. PubMed ID: 23134727
[TBL] [Abstract][Full Text] [Related]
22. Chromodomain Helicase DNA-Binding Protein 7 Is Suppressed in the Perinecrotic/Ischemic Microenvironment and Is a Novel Regulator of Glioblastoma Angiogenesis.
Boyd NH; Walker K; Ayokanmbi A; Gordon ER; Whetsel J; Smith CM; Sanchez RG; Lubin FD; Chakraborty A; Tran AN; Herting C; Hambardzumyan D; Yancey Gillespie G; Hackney JR; Cooper SJ; Jiao K; Hjelmeland AB
Stem Cells; 2019 Apr; 37(4):453-462. PubMed ID: 30629778
[TBL] [Abstract][Full Text] [Related]
23. HERVH-derived lncRNAs negatively regulate chromatin targeting and remodeling mediated by CHD7.
Hsieh FK; Ji F; Damle M; Sadreyev RI; Kingston RE
Life Sci Alliance; 2022 Jan; 5(1):. PubMed ID: 34663690
[No Abstract] [Full Text] [Related]
24. Genetic and expressional alterations of CHD genes in gastric and colorectal cancers.
Kim MS; Chung NG; Kang MR; Yoo NJ; Lee SH
Histopathology; 2011 Apr; 58(5):660-8. PubMed ID: 21447119
[TBL] [Abstract][Full Text] [Related]
25. De novo Splice Site Mutation of the CHD7 Gene in a Chinese Patient with Typical CHARGE Syndrome.
Wang S; Lin Y; Liang P; Li Q; Li W; Wang Z; Wang J; Chen J; Zha D
ORL J Otorhinolaryngol Relat Spec; 2022; 84(5):417-424. PubMed ID: 35078197
[TBL] [Abstract][Full Text] [Related]
26. Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis.
Li A; Chapuy B; Varelas X; Sebastiani P; Monti S
Sci Rep; 2019 Nov; 9(1):16904. PubMed ID: 31729402
[TBL] [Abstract][Full Text] [Related]
27. Identification of one novel CHD7 mutation in a patient from China with atypical CHARGE syndrome.
Cheng J; Ma D; Wu Y; Luo C; Huang C; Hu P; Zhang J; Jiang T; Xu Z
Gene; 2015 Oct; 571(2):298-302. PubMed ID: 26187070
[TBL] [Abstract][Full Text] [Related]
28. CHD7 regulates cardiovascular development through ATP-dependent and -independent activities.
Yan S; Thienthanasit R; Chen D; Engelen E; Brühl J; Crossman DK; Kesterson R; Wang Q; Bouazoune K; Jiao K
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28847-28858. PubMed ID: 33127760
[No Abstract] [Full Text] [Related]
29. Comprehensive analysis of the expression, prognosis, and immune infiltrates for CHDs in human lung cancer.
Lv Y; Lin W
Discov Oncol; 2022 Apr; 13(1):29. PubMed ID: 35467222
[TBL] [Abstract][Full Text] [Related]
30. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.
Zhao D; Lu X; Wang G; Lan Z; Liao W; Li J; Liang X; Chen JR; Shah S; Shang X; Tang M; Deng P; Dey P; Chakravarti D; Chen P; Spring DJ; Navone NM; Troncoso P; Zhang J; Wang YA; DePinho RA
Nature; 2017 Feb; 542(7642):484-488. PubMed ID: 28166537
[TBL] [Abstract][Full Text] [Related]
31. CHD7 targets active gene enhancer elements to modulate ES cell-specific gene expression.
Schnetz MP; Handoko L; Akhtar-Zaidi B; Bartels CF; Pereira CF; Fisher AG; Adams DJ; Flicek P; Crawford GE; Laframboise T; Tesar P; Wei CL; Scacheri PC
PLoS Genet; 2010 Jul; 6(7):e1001023. PubMed ID: 20657823
[TBL] [Abstract][Full Text] [Related]
32. Functional Insights into Chromatin Remodelling from Studies on CHARGE Syndrome.
Basson MA; van Ravenswaaij-Arts C
Trends Genet; 2015 Oct; 31(10):600-611. PubMed ID: 26411921
[TBL] [Abstract][Full Text] [Related]
33. The Chd family of chromatin remodelers.
Marfella CG; Imbalzano AN
Mutat Res; 2007 May; 618(1-2):30-40. PubMed ID: 17350655
[TBL] [Abstract][Full Text] [Related]
34. Metagenomic characterization of lysine acetyltransferases in human cancer and their association with clinicopathologic features.
Jiang Y; Guo X; Liu L; Rode S; Wang R; Liu H; Yang ZQ
Cancer Sci; 2020 May; 111(5):1829-1839. PubMed ID: 32162442
[TBL] [Abstract][Full Text] [Related]
35. Architects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromes.
Li W; Mills AA
Epigenomics; 2014; 6(4):381-95. PubMed ID: 25333848
[TBL] [Abstract][Full Text] [Related]
36. Presence of CHD1L over-expression is associated with aggressive tumor biology and is a novel prognostic biomarker for patient survival in human breast cancer.
Wu J; Zong Y; Fei X; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
PLoS One; 2014; 9(8):e98673. PubMed ID: 25153161
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of fbxl10/kdm2bb rescues chd7 morphant phenotype in a zebrafish model of CHARGE syndrome.
Balow SA; Pierce LX; Zentner GE; Conrad PA; Davis S; Sabaawy HE; McDermott BM; Scacheri PC
Dev Biol; 2013 Oct; 382(1):57-69. PubMed ID: 23920116
[TBL] [Abstract][Full Text] [Related]
38. Chd7 cooperates with Sox10 and regulates the onset of CNS myelination and remyelination.
He D; Marie C; Zhao C; Kim B; Wang J; Deng Y; Clavairoly A; Frah M; Wang H; He X; Hmidan H; Jones BV; Witte D; Zalc B; Zhou X; Choo DI; Martin DM; Parras C; Lu QR
Nat Neurosci; 2016 May; 19(5):678-689. PubMed ID: 26928066
[TBL] [Abstract][Full Text] [Related]
39. Chromatin gatekeeper and modifier CHD proteins in development, and in autism and other neurological disorders.
Muhammad T; Pastore SF; Good K; Ausió J; Vincent JB
Psychiatr Genet; 2023 Dec; 33(6):213-232. PubMed ID: 37851134
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a novel CHD7 CHARGE syndrome variant by integrated omics analyses.
Granadillo JL; Wegner DJ; Paul AJ; Willing M; Sisco K; Tedder ML; Sadikovic B; Wambach JA; Baldridge D; Cole FS;
Am J Med Genet A; 2021 Feb; 185(2):544-548. PubMed ID: 33184947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
